Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
  • Optimising radical treatment of vivax malaria with primaquine: adapting current dosing recommendations to develop optimised weight and age-based dosing regimens of primaquine
  • Developing innovative primaquine regimens for different regions to obviate the need to test for G6PD deficiency
  • CYP2D6 genetic variants and their impact on primaquine efficacy
  • Plasmodium vivax Controlled Human Infection Models (with HVCTU)
  • Studies on the roll out of the radical cure for P. vivax at village and health post level.